http://purl.org/np/RApHsKFnbS... RApHsKFnbS

links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance

http://www.w3.org/ns/prov#wasAttributedTo wasAttributedTo

https://orcid.org/0000-0002-3668-2627 Elif Ozkan

Elif Ozkan

2022-10-13T12:35:21.230Z

http://purl.org/np/RApHsKFnbS... RApHsKFnbS

links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance

http://www.w3.org/ns/prov#generatedAtTime generatedAtTime

2022-10-13T12:35:21.230396

Elif Ozkan

2022-10-13T12:35:21.230Z

http://purl.org/np/RApHsKFnbS... RApHsKFnbS

links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance

http://www.w3.org/ns/prov#wasQuotedFrom wasQuotedFrom

Atorvastatin and other statins are considered first-line treatment options for dyslipidemia. The increasing use of this class of drugs is largely attributed to the rise in cardiovascular diseases (CVD) An elevated cholesterol level (elevated low-density lipoprotein (LDL) levels) is a significant risk factor for the development of CVD. Statins were shown to reduce the incidences of all-cause mortality, including fatal and non-fatal CVD, as well as the need for surgical revascularization or angioplasty following a

Elif Ozkan

2022-10-13T12:35:21.230Z